Pooled Phenotypic Assay for Proteomic Target Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for drug discovery are limited in identifying and validating new therapeutic targets, particularly at the proteomic level, due to the complexity of protein interactions and low-throughput approaches, which hinder the identification of drug-binding sites for therapeutic intervention.
Innovation Solution
A method involving pooled phenotypic assay formats using peptide and nucleic acid libraries to screen mammalian cells with detectable reporters, allowing for the identification of compounds that inhibit cell signaling pathways and pinpointing protein interaction sites as potential drug targets, enabling a high-throughput and accurate linkage between targets and disease mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional genomic and transcriptomic level screening methods are used, then the screening process is manageable and sequential validation is feasible, but the scope of targets is limited to approximately 25,000 genes and cannot capture full proteomic complexity
Solution Approach 1:
The patent uses reporter gene copies (luciferase, GFP) to represent and measure the activity of endogenous genes and proteins. These reporter copies allow high-throughput screening of proteomic targets without directly manipulating each native gene, enabling expanded target scope while managing complexity through surrogate measurement systems
Solution Approach 2:
The patent introduces regulatory elements and reporter molecules as intermediaries between the target proteins and the measurement system. These intermediaries translate complex protein activities into quantifiable reporter signals, enabling systematic screening of proteomic targets that would otherwise be intractable
2Productivity
If high-throughput pooled phenotypic assays are implemented to screen the full proteome, then the screening capacity and target identification efficiency are dramatically improved, but the assay complexity and difficulty of functional validation increase substantially
Solution Approach 1:
The patent segments the screening process into distinct functional modules: (1) target gene/protein expression in mammalian cells, (2) pathway activity measurement via regulatory elements, and (3) reporter signal detection. This segmentation enables high-throughput pooled screening while maintaining the ability to validate individual targets by manipulating specific modules
Solution Approach 2:
The patent creates universal screening platforms using mammalian cells that can test multiple target genes and proteins simultaneously through pooled assays. The same cellular system and reporter architecture can be applied across different targets and pathways, enabling high productivity while using a standardized approach that simplifies validation
3Quantity of substance
If protein complexity and conformational diversity are fully considered to identify therapeutic targets, then the number of potential drug-binding sites increases significantly, but the ability to screen and validate each target becomes intractable
Solution Approach 1:
The patent uses reporter protein copies to represent the functional output of complex protein targets. Instead of directly screening and validating each protein conformation, the system measures reporter activity that reflects the net functional effect, making the large number of potential targets tractable while preserving the ability to identify specific binding sites through follow-up studies
Solution Approach 2:
The patent employs mammalian cells to self-express the target proteins and perform their native functions within a physiological context. The cells automatically handle protein folding, conformational dynamics, and interaction networks, eliminating the need for external systems to manage protein complexity while enabling high-throughput screening of functional outcomes
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
A method for the identification of new therapeutic targets and protein interaction sites for use in drug discovery. In particular the invention relates to a method for identifying inhibitors of a cell signalling pathway, the method comprising (1) providing a population of mammalian cells, each mammalian cell having an active cell signalling pathway and comprising: (a) a first heterologous nucleic acid comprising; (i) a nucleotide sequence encoding a first detectable reporter and, (ii) a constitutive regulatory element which is operably linked to the nucleotide sequence; and, (b) a second heterologous nucleic acid comprising: (i) a first nucleotide sequence encoding a repressor molecule, for example an RNA or protein, which inactivates, inhibits or suppresses expression of the first detectable reporter, (ii) a second nucleotide sequence encoding a second detectable reporter; and (iii) a signal-activated regulatory element which is activated by said cell signalling pathway, said signal-activated regulatory element being operably linked to the first and second nucleotide sequences, (2) introducing a library of test compounds into said population of mammalian cells, and; (3) determining the expression of the first and the second detectable reporters in one or more of the population of transfected cells, wherein expression of the first detectable reporter but not the second detectable reporter in a transfected cell is indicative that the test biomolecule expressed by the nucleic acid in the cell inhibits said cell signalling pathway.